Lishengpharma(SZ:002393) Xin Lang Cai Jing·2025-12-22 01:32Group 1 - The core viewpoint of the news is that Lisheng Pharmaceutical has shown fluctuations in its financing activities and stock performance, with a notable increase in net profit despite a slight decline in revenue [1][2]. Group 2 - On December 19, Lisheng Pharmaceutical's stock rose by 1.27%, with a trading volume of 52.99 million yuan. The financing buy-in amount was 3.7368 million yuan, while the financing repayment was 5.7458 million yuan, resulting in a net financing buy-in of -2.009 million yuan [1]. - As of December 19, the total balance of margin trading for Lisheng Pharmaceutical was 219 million yuan, which accounts for 4.23% of its circulating market value, indicating a low level compared to the past year [1]. - In terms of short selling, on December 19, Lisheng Pharmaceutical had no shares repaid but sold 1,300 shares, amounting to 26,900 yuan at the closing price. The short selling balance was 82,800 yuan, which is above the 90th percentile of the past year, indicating a high level [1]. Group 3 - As of October 20, the number of shareholders for Lisheng Pharmaceutical was 23,900, an increase of 0.13% from the previous period. The average circulating shares per person decreased by 0.13% to 10,479 shares [2]. - For the period from January to September 2025, Lisheng Pharmaceutical reported a revenue of 1.007 billion yuan, a year-on-year decrease of 1.61%. However, the net profit attributable to the parent company was 371 million yuan, reflecting a significant year-on-year growth of 119.05% [2]. Group 4 - In terms of dividends, Lisheng Pharmaceutical has distributed a total of 1.261 billion yuan since its A-share listing, with 255 million yuan distributed over the past three years [3].